Investigation of Short Course, High Dose Primaquine Treatment for Liver Stages of Plasmodium Vivax Infection [clinicaltrials:NCT02364583]

Bio2RDF uri

Investigation of Short Course, High Dose Primaquine Treatment for Liver Stages of Plasmodium Vivax Infection [clinicaltrials:NCT02364583]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT02364583

Bio2RDF identifier

NCT02364583

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT02364583

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT02364583

anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]

150

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT02364583 arm group 3dbaaf384b8561fcf8f5e81148d38366 [clinicaltrials_resource:NCT02364583/arm-group/3dbaaf384b8561fcf8f5e81148d38366]

NCT02364583 arm group 9469b1a1c794d9dd3bede915059c2ff8 [clinicaltrials_resource:NCT02364583/arm-group/9469b1a1c794d9dd3bede915059c2ff8]

NCT02364583 arm group edf7535e596314856e5a03e4292c9e60 [clinicaltrials_resource:NCT02364583/arm-group/edf7535e596314856e5a03e4292c9e60]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:b9e50cc685891d74e5772a8cf867ed55

brief summary [clinicaltrials_vocabulary:brief-summary]

This study specifically ...... f Plasmodium vivax infection.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Investigation of Short Course, ...... of Plasmodium Vivax Infection

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Safety and tolerability as measured by hemoglobin 2 months post baseline [clinicaltrials_resource:8b1bd093c06e8238b60779038cb70cdd]

Safety and tolerability as measured by hemoglobin 2 months post baseline [clinicaltrials_resource:d8d98e2b6c51e02b154c62f90044ba44]

Safety and tolerability as measured by hemoglobin 2 months post baseline [clinicaltrials_resource:e53848cd26e6766daf788ed210fcf816]

Safety and tolerability as measured by hemoglobin 2 months post baseline [clinicaltrials_resource:ff63954f447822739746f630d6de6b05]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Safety and tolerability as measured by hemoglobin 2 months post baseline [clinicaltrials_resource:23a6590153607e0eb90def9837738a68]

Safety and tolerability as measured by hemoglobin 2 months post baseline [clinicaltrials_resource:3ead76a5ddb3d9c864bee91d45ce20eb]

Safety and tolerability as measured by hemoglobin 2 months post baseline [clinicaltrials_resource:7cb59e13188df29802504c67595ebd51]

Safety and tolerability as measured by hemoglobin 2 months post baseline [clinicaltrials_resource:a0dea530b61f31225b9d4ff5016ef898]

Safety and tolerability as measured by hemoglobin 2 months post baseline [clinicaltrials_resource:ab7ea7e2d55c30795d8afd83697e8593]

Safety and tolerability as measured by hemoglobin 2 months post baseline [clinicaltrials_resource:b77d79c1848c8e87c07d6cd4a40b606a]

Safety and tolerability as measured by hemoglobin 2 months post baseline [clinicaltrials_resource:cbb68f7d4d62ae3f328f14ab9f21a40c]

Safety and tolerability as measured by hemoglobin 2 months post baseline [clinicaltrials_resource:d4924dbd211f48647f28e89d388c4611]

collaborator [clinicaltrials_vocabulary:collaborator]

Papua New Guinea Institute of Medical Research [clinicaltrials_resource:ff341700c67a0d0004bc8b9df9df4b7f]

completion date [clinicaltrials_vocabulary:completion-date]

2015-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

condition [clinicaltrials_vocabulary:condition]

Plasmodium Vivax [clinicaltrials_resource:30e6940706452281791e322f88c199c2]

country [clinicaltrials_vocabulary:country]

Papua New Guinea [clinicaltrials_resource:f670d3806d530c3e5cb1f31dca457751]

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT02364583 [clinicaltrials_resource:1dfff25627dbd365b1739fa0ab697011]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2014-11-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-02-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Papua New Guinea Institute of Medical Research [clinicaltrials_resource:ff341700c67a0d0004bc8b9df9df4b7f]

location [clinicaltrials_vocabulary:location]

PNG Institute of Medical Research [clinicaltrials_resource:2ad934472bb4faa9decb168a9cdbfae7]

nct id [clinicaltrials_vocabulary:nct-id]

NCT02364583

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

Safety, Tolerability and Pilot ...... of Plasmodium Vivax Infection

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

MRAC10.14

http://www.w3.org/2001/XMLSchema#string

overall contact [clinicaltrials_vocabulary:overall-contact]

Inoni Betuela, MD, PhD [clinicaltrials_resource:54ecb1003f924fe63d936d5d32034555]

overall contact backup [clinicaltrials_vocabulary:overall-contact-backup]

Inoni Betuela, MD, PhD [clinicaltrials_resource:36f70eee299d1896de9a54f1e203dbd7]

overall official [clinicaltrials_vocabulary:overall-official]

Inoni Betuela, MD, PhD [clinicaltrials_resource:2358333342c82a1253e64de54d844442]

overall status [clinicaltrials_vocabulary:overall-status]

Recruiting [clinicaltrials_resource:5231dee7156b84b0d1854de1a18dd169]

oversight [clinicaltrials_vocabulary:oversight]

Papua New Guinea: PNG Medical Research Advisory Committee [clinicaltrials_resource:813f848169d07413a49881418d8ab9d8]

phase [clinicaltrials_vocabulary:phase]

Phase 4 [clinicaltrials_resource:ec41833bc88cd90619c4d85c549688bd]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

source [clinicaltrials_vocabulary:source]

Papua New Guinea Institute of Medical Research [clinicaltrials_resource:ff341700c67a0d0004bc8b9df9df4b7f]

start date [clinicaltrials_vocabulary:start-date]

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT02364583 study design [clinicaltrials_resource:4038bd99b51b0f07fe46dea2940f7f7f]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT02364583

verification date [clinicaltrials_vocabulary:verification-date]

2015-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT02364583

http://www.w3.org/2001/XMLSchema#string

title

Investigation of Short Course, ...... of Plasmodium Vivax Infection

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Investigation of Short Course, ...... n [clinicaltrials:NCT02364583]

@en